{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:56:00Z","timestamp":1754110560836,"version":"3.37.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Several studies have shown that inflammatory bowel diseases (IBD) patients treated with thiopurines have an increased risk of developing skin cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Sources of data<\/jats:title><jats:p>This review is based on recent published literature regarding the use of thiopurines in IBD and skin malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of agreement<\/jats:title><jats:p>Exposure to thiopurines is significantly associated with nonmelanoma skin cancer, but not with melanoma. Primary and secondary prevention including sun-protective measures and regular dermatologic screening are recommended in IBD patients, particularly in those exposed to thiopurines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of controversy<\/jats:title><jats:p>Both when and how immunosuppressive therapy should be resumed in patients with a prior history of skin cancer still remain debatable topics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Growing points<\/jats:title><jats:p>The benefit\u2013risk balance between thiopurine therapy and risk of skin cancer should be evaluated in the drug decision process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas timely for developing research<\/jats:title><jats:p>The approval of new effective strategies requires the re-evaluation of the positioning of thiopurines within the therapeutic algorithm based on an increasingly individualized approach.<\/jats:p><\/jats:sec>","DOI":"10.1093\/bmb\/ldaa033","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:32:19Z","timestamp":1607315539000},"page":"107-117","source":"Crossref","is-referenced-by-count":8,"title":["Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases"],"prefix":"10.1093","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 4 Rita Levi Montalcini Street, Pieve Emanuele, 20090 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 4 Rita Levi Montalcini Street, Pieve Emanuele, 20090 Milan, Italy"},{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 5 all\u00e8e du Morvan, 54500 Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Correale","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD Center, Humanitas Clinical and Research Center, IRCCS, 56 Manzoni Street, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 5 all\u00e8e du Morvan, 54500 Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 4 Rita Levi Montalcini Street, Pieve Emanuele, 20090 Milan, Italy"},{"name":"Department of Gastroenterology, IBD Center, Humanitas Clinical and Research Center, IRCCS, 56 Manzoni Street, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2020121509334534900_ref1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020121509334534900_ref2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2020121509334534900_ref3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2020121509334534900_ref4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020121509334534900_ref5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: a call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020121509334534900_ref6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41575-019-0118-x","article-title":"Redefining the IBDs using genome-scale molecular phenotyping","volume":"16","author":"Furey","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020121509334534900_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284819853208","article-title":"New biologics and small molecules in inflammatory bowel disease: an update","volume":"12","author":"Sabino","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"2020121509334534900_ref8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","article-title":"JAK inhibition in inflammatory bowel diseas","volume":"13","author":"Olivera","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2020121509334534900_ref9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MIB.0000000000000243","article-title":"Cancer and immunomodulators in inflammatory bowel diseases","volume":"21","author":"Biancone","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2020121509334534900_ref10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/bmb\/ldl020","article-title":"Thiopurines, DNA damage, DNA repair and therapy-related cancer","volume":"79-80","author":"Karran","year":"2006","journal-title":"Br Med Bull"},{"key":"2020121509334534900_ref11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2020121509334534900_ref12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2020121509334534900_ref13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020121509334534900_ref14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2020121509334534900_ref15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"2020121509334534900_ref16","first-page":"390","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"143","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"2020121509334534900_ref17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan","year":"2010","journal-title":"Lancet"},{"key":"2020121509334534900_ref18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"2020121509334534900_ref19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"2020121509334534900_ref20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/00365521.2013.846402","article-title":"Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland","volume":"48","author":"Jussila","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2020121509334534900_ref21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"2020121509334534900_ref22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020121509334534900_ref23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","article-title":"Thiopurines in inflammatory bowel disease: new findings and perspectives","volume":"12","author":"Boer","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals","article-title":"Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A.) AZATHIOPRINE","key":"2020121509334534900_ref24"},{"key":"2020121509334534900_ref25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00007890-197210000-00001","article-title":"Malignant tumors arising de novo in immunosuppressed organ transplant recipients","volume":"14","author":"Penn","year":"1972","journal-title":"Transplantation"},{"key":"2020121509334534900_ref26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Medicine: azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O\u2019Donovan","year":"2005","journal-title":"Science"},{"volume-title":"Azathioprine Tablets 25mg - Summary of Product Characteristics (SmPC)","year":"20 2020","key":"2020121509334534900_ref27"},{"key":"2020121509334534900_ref28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2020121509334534900_ref29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2020121509334534900_ref30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.14105","article-title":"Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-Centre cohort study","volume":"31","author":"Clowry","year":"2017","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2020121509334534900_ref31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-4632.2010.04474.x","article-title":"Ultraviolet radiation and skin cancer","volume":"49","author":"Narayanan","year":"2010","journal-title":"Int J Dermatol"},{"key":"2020121509334534900_ref32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","article-title":"Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2020121509334534900_ref33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"2020121509334534900_ref34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2020121509334534900_ref35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.14309\/ajg.0000000000000679","article-title":"Repeated occurrences of basal cell cancer in patients with inflammatory bowel disease treated with immunosuppressive medications","volume":"115","author":"Khan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2020121509334534900_ref36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"2020121509334534900_ref37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2020121509334534900_ref38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2009.01289.x","article-title":"Photoprotection: a review of the current and future technologies","volume":"23","author":"Wang","year":"2010","journal-title":"Dermatol Ther"},{"key":"2020121509334534900_ref39","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1097\/MIB.0000000000000665","article-title":"Photosensitivity to ultraviolet light in patients with inflammatory bowel disease newly initiating immunosuppressive therapy","volume":"22","author":"Long","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2020121509334534900_ref40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive Care in Inflammatory Bowel Disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2020121509334534900_ref41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MOG.0000000000000538","article-title":"Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease","volume":"35","author":"Brenner","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"2020121509334534900_ref42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation"},{"key":"2020121509334534900_ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284818817293","article-title":"Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?","volume":"12","author":"Sebastian","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"2020121509334534900_ref44","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020121509334534900_ref45","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ecco-jcc\/jjy006","article-title":"Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020121509334534900_ref46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med"},{"key":"2020121509334534900_ref47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"2020121509334534900_ref48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020121509334534900_ref49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MIB.0000000000000583","article-title":"The evolving role of Thiopurines for inflammatory bowel disease","volume":"22","author":"Rosen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2020121509334534900_ref50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11938-019-00249-y","article-title":"The evolving role of Thiopurines in inflammatory bowel disease","volume":"17","author":"Kapur","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2020121509334534900_ref51","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/136\/1\/107\/34903696\/ldaa033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/136\/1\/107\/34903696\/ldaa033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T20:48:04Z","timestamp":1618606084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/136\/1\/107\/5983608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldaa033","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"type":"print","value":"0007-1420"},{"type":"electronic","value":"1471-8391"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,11,16]]}}}